INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS

被引：1
|
作者：
Rousseau, B. [1 ]
Poinas, A. [1 ]
Oliver, L. [1 ]
Collings, H. [1 ]
机构：
[1] Adelphi Values Ltd, Bollington, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1787
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP251
引用
收藏
页码：A695 / A696
页数：2
相关论文
共 50 条
  • [1] Pricing and reimbursement of orphan drugs in Italy
    Lopatriello, S.
    Schivazappa, C.
    Negrini, C.
    Berto, P.
    VALUE IN HEALTH, 2006, 9 (06) : A208 - A209
  • [2] PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA
    Kumar, J.
    Bachman, E. M.
    VALUE IN HEALTH, 2011, 14 (03) : A29 - A29
  • [3] REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
    Cheng, C. Y.
    Chan, H. W.
    Fang, C. H.
    VALUE IN HEALTH, 2019, 22 : S856 - S856
  • [4] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [5] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
  • [6] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [7] PRICING AND REIMBURSEMENT SYSTEM OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Prochazkova, M.
    Kubickova, P.
    Mazelova, J.
    Hambalek, J.
    Heislerova, M.
    VALUE IN HEALTH, 2013, 16 (07) : A474 - A474
  • [8] Pricing of orphan drugs
    Leonard, J. V.
    Richmond, S.
    LANCET, 2009, 373 (9662): : 462 - 462
  • [9] Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
    Stawowczyk, Ewa
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    Bobinski, Rafal
    Siwiec, Jacek
    Panteli, Dimitra
    Eckhardt, Helene
    Simoens, Steven
    Agusti, Antonia
    Dooms, Marc
    Pilc, Andrzej
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [10] EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION MAKING FOR ORPHAN DRUGS IN ASIA
    Tan, S.
    Dummett, H.
    Kirpekar, S.
    Guan, Q.
    Priest, V. L.
    VALUE IN HEALTH, 2012, 15 (07) : A621 - A622
12345